(Q40197234)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

main subject

phase II clinical trial

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Giorgia Mangili

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ettore Capoluongo

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

Maria Gabriella Ferrandina

3 March 2020

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

G Scambia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

S Pignata

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

R Sorio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

G Amadio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

S Lepori

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

A Mosconi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Pisano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

G Maltese

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

R Sabbatini

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

G Artioli

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

T Gamucci

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M Di Napoli

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

V Ludovini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

F Raspagliesi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

17 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

487-493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

Integrated genomic analyses of ovarian carcinoma

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Role of homologous recombination in trabectedin-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV608

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV608

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26681678%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference